No Data
No Data
Third Harmonic Bio Advances THB335 for Inflammatory Diseases
Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In Growth
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
$THRD Stock Is up 17% Today. Here's What We See in Our Data.
Morgan Stanley Maintains Third Harmonic Bio(THRD.US) With Hold Rating, Maintains Target Price $5
Third Harmonic Bio Price Target Cut to $5.00/Share From $20.00 by Morgan Stanley
Edozz : yep.
Edozz : got it when it was down 34% yesterday. unloade at +15% today
Trytosaveabit OP Edozz : Nicely done! Congrats
